Jazz Pharmaceuticals Files 8-K on Financials
Ticker: JAZZ · Form: 8-K · Filed: Jul 31, 2024 · CIK: 1232524
| Field | Detail |
|---|---|
| Company | Jazz Pharmaceuticals PLC (JAZZ) |
| Form Type | 8-K |
| Filed Date | Jul 31, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Jazz Pharma dropped an 8-K on 7/31 detailing financials - check it out.
AI Summary
Jazz Pharmaceuticals plc filed an 8-K on July 31, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to its business operations. The company is incorporated in Ireland and its principal executive offices are located in Dublin.
Why It Matters
This filing provides an update on Jazz Pharmaceuticals' financial performance and operational status, which is crucial for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing and does not indicate any immediate or significant risks.
Key Players & Entities
- Jazz Pharmaceuticals plc (company) — Registrant
- July 31, 2024 (date) — Date of Report
- Ireland (location) — State of Incorporation
- Dublin (location) — Address of principal executive offices
FAQ
What specific financial information is being reported in this 8-K?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K report filed?
The report was filed on July 31, 2024.
Where are Jazz Pharmaceuticals' principal executive offices located?
The principal executive offices are located at Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland.
What is the company's state of incorporation?
The company is incorporated in Ireland.
What is the Commission File Number for Jazz Pharmaceuticals?
The Commission File Number is 001-33500.
Filing Stats: 556 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-07-31 16:06:24
Key Financial Figures
- $0.0001 — stered Ordinary shares, nominal value $0.0001 per share JAZZ The Nasdaq Stock Marke
Filing Documents
- jazz-20240731.htm (8-K) — 28KB
- a2q24financialpr.htm (EX-99.1) — 554KB
- jazzpharma_logoxfullcolora.jpg (GRAPHIC) — 117KB
- 0001232524-24-000065.txt ( ) — 912KB
- jazz-20240731.xsd (EX-101.SCH) — 2KB
- jazz-20240731_lab.xml (EX-101.LAB) — 23KB
- jazz-20240731_pre.xml (EX-101.PRE) — 13KB
- jazz-20240731_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On July 31, 2024, Jazz Pharmaceuticals plc (the "Company") issued a press release (the "Press Release") announcing financial results for the Company for the quarter ended June 30, 2024. A copy of the Press Release is furnished as Exhibit 99.1 to this current report. The information in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this current report shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this current report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated July 31, 2024. 104 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY By: /s/ Philip L. Johnson Name: Philip L. Johnson Title: Executive Vice President and Chief Financial Officer Date: July 31, 2024